Torsadogenic Risk of Antipsychotics: Combining Adverse Event Reports with Drug Utilization Data across Europe

A Computerized Physician Order Entry Set Designed to Improve Safety of Intravenous Haloperidol Utilization

(2013) Andrew J. Muzyk et al.   DRUG SAFETY

Global Patterns of Adverse Drug Reactions Over a Decade

(2013) Lise Aagaard et al.   DRUG SAFETY

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database

(2013) Elisabetta Poluzzi et al.   DRUG SAFETY

Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications

(2013) M. Bennie et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis

(2013) Ruben G. Duijnhoven et al.   PLOS MEDICINE

Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011

(2012) Chris P Stephenson et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Examination of Baseline Risk Factors for QTc Interval Prolongation in Patients Prescribed Intravenous Haloperidol

(2012) Andrew J. Muzyk et al.   DRUG SAFETY

Adverse drug reactions: Analysis of spontaneous reporting system in Europe in 2007–2009

(2012) Jindrich Srba et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Treatment-emergent adverse events associated with atypical antipsychotics

(2012) Danielle S Cha et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

(2012) S Miyamoto et al.   MOLECULAR PSYCHIATRY

A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class

(2012) Keith B. Hoffman et al.   PLoS One

Possible ways to enhance renin–angiotensin prescribing efficiency: Republic of Serbia as a case history?

(2012) Marija Kalaba et al.   Journal of Comparative Effectiveness Research

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

(2011) E. Raschi et al.   ACTA DIABETOLOGICA

National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders

(2011) Jonathan S. Comer et al.   AMERICAN JOURNAL OF PSYCHIATRY

Trends in Antipsychotic Use in Dementia 1999-2007

(2011) Helen C. Kales et al.   ARCHIVES OF GENERAL PSYCHIATRY

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

(2011) G. C. Alexander et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Correlation versus Causation? Pharmacovigilance of the Analgesic Flupirtine Exemplifies the Need for Refined Spontaneous ADR Reporting

(2011) Nora Anderson et al.   PLoS One

Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case

(2011) Carla Meyer-Massetti et al.   International Journal of Clinical Pharmacy

Influence of Patient Co-Payments on Atypical Antipsychotic Choice in Poland

(2011) Magda Wladysiuk et al.   Applied Health Economics and Health Policy

Impact of FDA Black Box Advisory on Antipsychotic Medication Use

(2010) E. Ray Dorsey   ARCHIVES OF INTERNAL MEDICINE

Antimicrobials and the Risk of Torsades de Pointes

(2010) Elisabetta Poluzzi et al.   DRUG SAFETY

The FDA extended warning for intravenous haloperidol and torsades de pointes: How should institutions respond?

(2010) Carla Meyer-Massetti et al.   Journal of Hospital Medicine

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

(2010) Christine Rummel-Kluge et al.   SCHIZOPHRENIA RESEARCH

Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies

(2009) H. Verdoux et al.   ACTA PSYCHIATRICA SCANDINAVICA

The Nordic Countries as a Cohort for Pharmacoepidemiological Research

(2009) Kari Furu et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Sudden death in patients receiving drugs tending to prolong the QT interval

(2009) Kate Jolly et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Time-to-Signal Comparison for Drug Safety Data-Mining Algorithms vs. Traditional Signaling Criteria

(2009) AM Hochberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Decision support methods for the detection of adverse events in post-marketing data

(2009) M. Hauben et al.   DRUG DISCOVERY TODAY

The use of driving impairing medicines: a European survey

(2009) Silvia Ravera et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?

(2009) Michela Nosè et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death

(2009) Wayne A. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)

(2009) Elisabetta Poluzzi et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Psychotropic medication use among nursing home residents in Austria: a cross-sectional study

(2009) Eva Mann et al.   BMC Geriatrics

Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period

(2008) Emanuel Raschi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis

(2008) E. Valiyeva et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET